Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit managers. Its CenterWell segment operates full-service, value-based senior focused primary care centers under the Conviva Senior Primary Care and CenterWell Senior Primary Care brands; a management services organization; CenterWell Home Health, a home health provider; and OneHome, which manages post-acute patient needs, as well as provides pharmacy and hospice solutions. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $129.7B | - | $1.2B | $375M | 6.7% | 10.1% | -1.6% |
| 2024 | $117.8B | - | $1.2B | $2.4B | 7.4% | 10.7% | -51.5% |
| 2023 | $106.4B | - | $2.5B | $3.0B | 15.3% | 14.5% | -11.3% |
| 2022 | $92.9B | - | $2.8B | $3.5B | 18.3% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 92,870 | 106,374 | 117,761 | 129,664 |
| Operating Revenue | - | 92,870 | 106,374 | 117,761 | 129,664 |
| Total Expenses | - | 89,302 | 102,991 | 116,040 | 128,109 |
| EBIT | - | 3,969 | 3,876 | 2,381 | 2,186 |
| Interest Expense | - | 401 | 493 | 660 | 631 |
| Net Interest Income | - | -401 | -493 | -660 | -631 |
| Interest Expense Non Operating | - | 401 | 493 | 660 | 631 |
| Net Non Operating Interest Income Expense | - | -401 | -493 | -660 | -631 |
| Pretax Income | - | 3,568 | 3,383 | 1,721 | 1,555 |
| Tax Provision | - | 762 | 836 | 413 | 250 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 50.61 | 0 | 0 | -11.66 |
| Net Income Continuous Operations | - | 2,802 | 2,484 | 1,214 | 1,203 |
| Net Income From Continuing And Discontinued Operation | - | 2,806 | 2,489 | 1,207 | 1,188 |
| Net Income From Continuing Operation Net Minority Interest | - | 2,806 | 2,489 | 1,207 | 1,188 |
| Net Income | - | 2,806 | 2,489 | 1,207 | 1,188 |
| Net Income Common Stockholders | - | 2,806 | 2,489 | 1,207 | 1,188 |
| Net Income Including Noncontrolling Interests | - | 2,802 | 2,484 | 1,214 | 1,203 |
| Normalized Income | - | 2,619.61 | 2,489 | 1,207 | 1,243.34 |
| Diluted NI Availto Com Stockholders | - | 2,806 | 2,489 | 1,207 | 1,188 |
| Basic Average Shares | - | 126.42 | 123.87 | 120.57 | 120.45 |
| Diluted Average Shares | - | 127.09 | 124.44 | 120.87 | 120.83 |
| Reconciled Depreciation | - | 845 | 917 | 968 | 824 |
| Total Unusual Items | - | 237 | 0 | 0 | -67 |
| Total Unusual Items Excluding Goodwill | - | 237 | 0 | 0 | -67 |
| Minority Interests | - | 4 | 5 | -7 | -15 |
| Earnings From Equity Interest Net Of Tax | - | -4 | -63 | -94 | -102 |
| Special Income Charges | - | 237 | 0 | 0 | -67 |
| Other Special Charges | - | -237 | - | - | 67 |
| Depreciation And Amortization In Income Statement | - | 709 | 779 | 839 | 698 |
| Other Operating Expenses | - | 12,739 | 13,325 | 13,877 | 15,901 |
| Loss Adjustment Expense | - | 75,690 | 88,394 | 100,664 | 110,812 |
| Net Policyholder Benefits And Claims | - | 75,690 | 88,394 | 100,664 | 110,812 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Humana Inc.this co. | HUM | $42.0B | 35.35 | 2.38 | 6.7% | - |
| Edwards Lifesciences Corporation | EW | $50.4B | 46.91 | 4.87 | 10.4% | 33.19 |
| Cardinal Health, Inc. | CAH | $47.2B | 30.27 | -16.99 | -56.1% | 16.71 |
| IDEXX Laboratories, Inc. | IDXX | $44.5B | 42.05 | 27.75 | 66.0% | 30.06 |
| Becton, Dickinson and Company | BDX | $41.2B | 24.56 |
| - |
| - |
| - |
| - |
| 1.62 |
| 6.6% |
| 12.06 |
| Alnylam Pharmaceuticals, Inc. | ALNY | $40.5B | 129.21 | 51.37 | 39.8% | 61.62 |
| Agilent Technologies, Inc. | A | $39.1B | 29.99 | 5.80 | 19.3% | 22.15 |
| Waters Corporation | WAT | $37.0B | 57.52 | 14.43 | 25.1% | 36.74 |
| Zoetis Inc. | ZTS | $33.3B | 12.47 | 10.01 | 80.2% | 9.90 |
| Peer Median | - | 36.16 | 7.90 | 22.2% | 26.11 | |
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historically, Apr has averaged the highest return (+6.8%); Jan the lowest (-8.2%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -23.8%Negative MonthJan 2026: -23.79% | -2.4%Negative MonthFeb 2026: -2.39% | -9.0%Negative MonthMar 2026: -9.00% | +36.4%Positive MonthApr 2026: +36.36% | +29.2%Positive MonthMay 2026: +29.17% | +30.1%Positive MonthJun 2026: +30.06% | -8.4%Negative MonthJul 2026: -8.40% | +3.9%*Positive MonthAug 2026: +3.89% | — | — | — | — |
| 2025 | +15.6%Positive MonthJan 2025: +15.58% | -7.8%Negative MonthFeb 2025: -7.78% | -2.2%Negative MonthMar 2025: -2.15% | -0.9%Neutral MonthApr 2025: -0.89% | -11.1%Negative MonthMay 2025: -11.10% | +4.9%Positive MonthJun 2025: +4.87% | +2.2%Positive MonthJul 2025: +2.20% | +21.5%Positive MonthAug 2025: +21.53% | -14.3%Negative MonthSep 2025: -14.32% | +6.9%Positive MonthOct 2025: +6.93% | -11.7%Negative MonthNov 2025: -11.65% | +4.2%Positive MonthDec 2025: +4.22% |
| 2024 | -17.4%Negative MonthJan 2024: -17.42% | -7.3%Negative MonthFeb 2024: -7.34% | -1.0%Neutral MonthMar 2024: -1.03% | -12.9%Negative MonthApr 2024: -12.87% | +18.5%Positive MonthMay 2024: +18.55% | +4.3%Positive MonthJun 2024: +4.34% | -3.2%Negative MonthJul 2024: -3.22% | -2.0%Neutral MonthAug 2024: -1.97% | -10.6%Negative MonthSep 2024: -10.64% | -18.6%Negative MonthOct 2024: -18.60% | +15.0%Positive MonthNov 2024: +14.95% | -14.4%Negative MonthDec 2024: -14.40% |
| 2023 | -0.1%Neutral MonthJan 2023: -0.10% | -3.3%Negative MonthFeb 2023: -3.26% | -1.9%Neutral MonthMar 2023: -1.93% | +9.3%Positive MonthApr 2023: +9.28% | -5.4%Negative MonthMay 2023: -5.40% | -10.9%Negative MonthJun 2023: -10.91% | +2.2%Positive MonthJul 2023: +2.17% | +1.1%Neutral MonthAug 2023: +1.05% | +5.4%Positive MonthSep 2023: +5.39% | +7.6%Positive MonthOct 2023: +7.64% | -7.4%Negative MonthNov 2023: -7.41% | -5.6%Negative MonthDec 2023: -5.58% |
| 2022 | -15.4%Negative MonthJan 2022: -15.38% | +10.7%Positive MonthFeb 2022: +10.65% | +0.2%Neutral MonthMar 2022: +0.20% | +2.2%Positive MonthApr 2022: +2.16% | +2.2%Positive MonthMay 2022: +2.18% | +3.0%Positive MonthJun 2022: +3.05% | +3.0%Positive MonthJul 2022: +2.98% | -0.0%Neutral MonthAug 2022: -0.05% | +0.7%Neutral MonthSep 2022: +0.71% | +15.0%Positive MonthOct 2022: +15.02% | -1.5%Neutral MonthNov 2022: -1.47% | -6.9%Negative MonthDec 2022: -6.86% |
| 2021 | — | — | — | — | -1.7%Neutral MonthMay 2021: -1.69% | +1.1%Neutral MonthJun 2021: +1.15% | -3.8%Negative MonthJul 2021: -3.81% | -4.8%Negative MonthAug 2021: -4.80% | -4.0%Negative MonthSep 2021: -4.01% | +19.0%Positive MonthOct 2021: +19.02% | -9.4%Negative MonthNov 2021: -9.38% | +10.5%Positive MonthDec 2021: +10.52% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
